Clinical Takeaway
In this phase 3 trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term follow-up extending to approximately one year. The trial used a rigorous randomized, double-blind, placebo-controlled design across multiple centers, making it one of the more methodologically robust cannabis studies conducted for this condition. Results from this scale of trial carry meaningful weight for clinicians considering cannabinoid options for patients with inadequately managed chronic low back pain.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by evaluating full-spectrum cannabis extract as a treatment option for chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic therapies demonstrate limited efficacy and carry significant adverse effect profiles. The rigorous double-blind, placebo-controlled design with 820 participants and extended follow-up provides the evidence quality necessary to inform clinical decision-making regarding cannabis-based therapeutics as an alternative or adjunctive treatment for CLBP. Given the opioid crisis and inadequacy of conventional analgesics, demonstration of safety and efficacy in this large, well-controlled trial could establish a new evidence-based treatment option for one of
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🏥 This phase 3 trial adds meaningful data to the limited RCT evidence for cannabis-based medicine in chronic low back pain, a condition where patients often face real therapeutic constraints with conventional analgesics. The relatively large sample size and double-blind design strengthen confidence compared to many cannabis studies, though we should note that full-spectrum extracts introduce variable cannabinoid and terpene profiles that may complicate standardization and reproducibility across clinical settings. The 12-week treatment window and 6-month open-label extension provide reasonable timeframes for assessing both efficacy and safety signals, though longer-term tolerability data and comparative effectiveness against established physical therapy or multimodal approaches would further inform clinical decision-making. Important caveats include the need to examine effect sizes and safety outcomes in the full published results, as well as how well the study population reflects the diverse CLBP phenotypes seen in primary care. Clinically, if VER-01 demonstrates meaningful pain reduction with a favorable safety profile, it could offer
| |